Linear Growth Characteristics of Untreated Congenitally Growth Hormone Deficient (CGHD) Infants from Birth to One Year of Age

Abstract Context Patients with aggrecan (ACAN) deficiency present with dominantly inherited short stature, often with advanced skeletal maturation and premature growth cessation. There is a paucity of information on the effects of growth-promoting interventions. Objective The aim of this study was to evaluate the efficacy and safety of recombinant human growth hormone (rhGH) therapy on linear growth in children with ACAN deficiency. Design and Setting Open-label, single-arm, prospective study at Cincinnati Children’s Hospital Medical Center. Patients Ten treatment-naïve patients were recruited. Inclusion criteria were: a confirmed heterozygous mutation in ACAN, age ≥ 2 years, pre-pubertal, bone age (BA) ≥ chronological age (CA), and normal IGF-I concentration. Intervention Treatment with rhGH (50 mcg/kg/day) over one year. Main Outcome Measure(s) Main outcomes measured were height velocity (HV) and change in (Δ) height SD (HtSDS). Results Ten patients (six females) were enrolled with median CA of 5.6 yrs (range 2.4 to 9.7). Baseline median HtSDS was -2.5 (range -4.3 to -1.1). Median baseline BA was 6.9 yrs (range 2.5 to 10.0), with median BA/CA of 1.2 (range 0.9 to 1.5). Median pre-treatment HV was 5.2 cm/y (range 3.8 to 7.1), increased to 8.3 cm/y (range 7.3 to 11.2) after one year of therapy (p=0.004). Median ΔHtSDS after one year was +0.62 (range +0.35 to +1.39) (p=0.002). Skeletal maturation did not advance inappropriately (median Δ BA/CA -0.1, p=0.09). No adverse events related to rhGH were observed. Conclusion Treatment with rhGH improved linear growth in a cohort of patients with short stature due to ACAN deficiency.

Download Full-text

Linear Growth Characteristics of Congenitally GH-Deficient Infants from Birth to One Year of Age

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem.86.12.8068 ◽

2001 ◽

Vol 86 (12) ◽

pp. 5691-5694 ◽

Cited By ~ 9

Author(s):

Susan Pena-Almazan ◽

John Buchlis ◽

Susan Miller ◽

Barbara Shine ◽

Margaret MacGillivray

Keyword(s):

Linear Growth ◽

Growth Characteristics ◽

One Year

Download Full-text

Imbalance in the oxygen-transporting properties of erythrocytes and the blood antioxidant system in growth hormone deficient children before therapy and after one year of recombinant growth hormone therapy

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0034-1372327 ◽

2014 ◽

Vol 122 (03) ◽

Author(s):

M Pankratova ◽

M Faassen ◽

T Shiryaeva ◽

V Peterkova ◽

S Kovalenko ◽

...

Keyword(s):

Growth Hormone ◽

Hormone Therapy ◽

Antioxidant System ◽

Growth Hormone Therapy ◽

Recombinant Growth Hormone ◽

One Year

Download Full-text

An investigation into the age and developmental stage related association between plasma concentrations of leptin and growth hormone, linear growth velocity, body mass index and body surface area in boys between the ages of 1 and 20 years

Endocrine Abstracts ◽

10.1530/endoabs.70.aep850 ◽

2020 ◽

Author(s):

Naseem Afzaal Ahmed ◽

Mazhar Qayyum ◽

Maleeha Akram ◽

Fahim Tahir ◽

Kiran Afshan ◽

...

Keyword(s):

Body Mass Index ◽

Growth Hormone ◽

Developmental Stage ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Growth Velocity ◽

Linear Growth ◽

Plasma Concentrations ◽

Related Association

Download Full-text

DETERMINATION OF AFTER-RIPENING PERIOD AND HORMONAL RESPONSE OF OROBANCHE SOLMSII C.D. CLARKE SEEDS

Ecoprint An International Journal of Ecology ◽

10.3126/eco.v11i1.149 ◽

1970 ◽

Vol 11 (1) ◽

Author(s):

A. Bista ◽

G. B. Khattri ◽

B. D. Acharya ◽

S. C. Srivastava

Keyword(s):

Growth Hormone ◽

Seed Germination ◽

Key Words ◽

Incubation Period ◽

Seed Set ◽

Summer Season ◽

Conditioning Period ◽

Root Parasite ◽

One Year

To find out the ability of Orobanche seeds to germinate immediately after seed set, seeds were germinated periodically at an interval of three months for one year in GR24. Some Orobanche seeds were capable of germination immediately after seed set but most required about nine months as after ripening or incubation period to be able to germinate. The phenomenon of after ripening in Orobanche seeds could be taken as an ecological measure to dormant over following unfavorable wet summer season. The growth hormone studies on Orobanche seed germination have shown that GA3 at a concentration of 100 ppm substantially enhanced seed germination when applied during pre-conditioning period. NAA showed some stimulatory effect at 0.5 - 1.0 ppm when applied during post-conditioning period but the hormone if applied during pre-conditioning period inhibited the germination. Kinetin failed to stimulate the germination at all the concentrations tested. Key words: Germination, root-parasite, hormone. Ecoprint Vol.11(1) 2004.

Download Full-text

The Effects of Recombinant Human Growth Hormone on Linear Growth in Children with Crohn's Disease and Short Stature

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem.2007.20.12.1315 ◽

2007 ◽

Vol 20 (12) ◽

Cited By ~ 10

Author(s):

S C. Wong ◽

K. Hassan ◽

P. McGrogan ◽

L.T. Weaver ◽

S.F. Ahmed

Keyword(s):

Growth Hormone ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Short Stature ◽

Human Growth Hormone ◽

Linear Growth ◽

Recombinant Human Growth Hormone ◽

Human Growth

Download Full-text

The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2020-0287 ◽

2020 ◽

Vol 33 (12) ◽

pp. 1577-1588

Author(s):

George Paltoglou ◽

Ioannis Dimitropoulos ◽

Georgia Kourlaba ◽

Evangelia Charmandari

Keyword(s):

Systematic Review ◽

Growth Hormone ◽

Short Stature ◽

Human Growth Hormone ◽

Adult Height ◽

Linear Growth ◽

Meta Analysis ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Idiopathic Short Stature

AbstractObjectivesIdiopathic short stature (ISS) is a recognized, albeit a controversial indication for treatment with recombinant human growth hormone (rhGH).The objective of the present study was to conduct a systematic review of the literature and meta-analyses of selected studies about the use of rhGH in children with ISS on linear growth and adult height (AH).MethodsA systematic literature search was conducted to identify relevant studies published till February 28, 2017 in the following databases: Medline (PubMed), Scopus and Cochrane Central Registry of Controlled Trials. After exclusion of duplicate studies, 3,609 studies were initially identified. Of those, 3,497 studies were excluded during the process of assessing the title and/or the abstract. The remaining 112 studies were evaluated further by assessing the full text; 21 of them fulfilled all the criteria in order to be included in the current meta-analysis.ResultsChildren who received rhGH had significantly higher height increment at the end of the first year, an effect that persisted in the second year of treatment and achieved significantly higher AH than the control group. The difference between the two groups was equal to 5.3 cm (95% CI: 3.4–7 cm) for male and 4.7 cm (95% CI: 3.1–6.3 cm) for female patients.ConclusionIn children with ISS, treatment with rhGH improves short-term linear growth and increases AH compared with control subjects. However, the final decision should be made on an individual basis, following detailed diagnostic evaluation and careful consideration of both risks and benefits of rhGH administration.

Download Full-text

Changes In Prothrombin And Activated Partial Thromboplastin Time During Replacement Therapy With Human Recombinant Growth Hormone In Growth Hormone Deficient Adults

American Journal of Clinical Pathology ◽

10.1093/ajcp/aqaa161.224 ◽

2020 ◽

Vol 154 (Supplement_1) ◽

pp. S102-S103

Author(s):

Y S Kamel

Keyword(s):

Growth Hormone ◽

Replacement Therapy ◽

Healthy Subjects ◽

Recombinant Growth Hormone ◽

Gh Replacement ◽

Coagulation Tests ◽

Before And After ◽

Human Recombinant Growth Hormone ◽

Male Patients ◽

One Year

Abstract Introduction/Objective The aim of this study was to investigate the effects of GH administration on basic coagulation parameters: PT, aPTT and fibrinogen concentrations in adult GHD patients before and during one year of GH replacement. Methods Twenty-one adult patients with severe GHD (mean age +/- SE: 38.6 +/- 2.8 years) were included in this hospital based, prospective, interventional study. All patients were treated with rhGH for 12 months (GH dose: 0.4 mg/day for male and 0.6 mg/day for female patients). IGF-1 concentrations were determined using RIA-INEP kits. Basic coagulation tests, i.e. aPTT and fibrinogen concentrations, were measured before and after 3, 6 and 12 months of treatment with rhGH. Control values were obtained from fourteen “healthy” subjects matched by age, sex and body mass index (BMI). Results At baseline, we observed no significant differences in PT, aPTT and fibrinogen values between GHD and healthy subjects. IGF-1 concentrations increased significantly within 3 months of GH therapy (8.2 +/- 1.5 vs. 24.2 +/- 2.9 nmol/l, p <0.05) and remained stable thereafter. A significant increase in PT values, which was more pronounced in female subjects, was noted after 6 and 12 months of treatment with GH. aPTT values increased significantly after 12 months of treatment only in male patients (28.8 +/- 4.6 vs. 39.7 +/- 2.1 s.; p <0.05). No significant changes in fibrinogen concentrations were found during the study. Conclusion Twelve months of GH replacement therapy led to a significant increase in PT and aPTT values in adult GHD patients, while fibrinogen concentrations did not change. Changes in PT were more pronounced in female GHD patients, while an increase in aPTT values was observed only in male patients with GHD. The clinical significance of these changes needs further evaluation.

Download Full-text